Summary
EudraCT Number: 2008-004628-21
Sponsor's Protocol Code Number: SAMDOCET
National Competent Authority: France - ANSM 
Clinical Trial Type: EEA CTA
Trial Status: Ongoing
Date on which this record was first entered in the EudraCT database: 2009-06-22
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004628-21/FR/

A. Protocol Information
A.1 Member State Concerned: France - ANSM
A.2 EudraCT number: 2008-004628-21
A.3 Full title of the trial: A multicenter phase III randomized study of 153Sm-EDTMP and Docetaxel + Prednisone versus Docetaxel + Prednisone in Taxane-naive patients with metastatic hormone-refractory prostate cancer.
A.3.2 Name or abbreviated title of the trial where available: SAMDOCET
A.4.1 Sponsor's protocol code number: SAMDOCET
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Azienda Ospedaliero-Universitaria Pisana
B.1.3.4	Country: Italy
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: QUADRAMET
D.2.1.1.2 Name of the Marketing Authorisation holder: CIS bio international
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Injection*
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: Yes
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: TAXOTERE
D.2.1.1.2 Name of the Marketing Authorisation holder: AVENTIS PHARMA SA
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Intravenous infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Cortancyl
D.2.1.1.2 Name of the Marketing Authorisation holder: Sanofi-Aventis
D.2.1.2 Country which granted the Marketing Authorisation: France
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: PREDNISONE
D.3.9.1 CAS number: 53032
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 5 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Hormone refractory prostate cancer with bone metastases
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 9.1
E.1.2 Level: LLT
E.1.2 Classification code: 10036909
E.1.2 Term: Prostate cancer metastatic
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To compare the time-to-progression (TTP) of 153Sm-EDTMP and Docetaxel + Prednisone (Arm 1) to Docetaxel + Prednisone (Arm 2).
E.2.2 Secondary objectives of the trial: Comparison between the treatment arms of:
	Tumor response
	Overall survival
	Quality of life
	Pain assessment
	Safety

E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: 1.	Histologically confirmed diagnosis of prostate cancer.
2.	Hormone-refractory disease as defined in by two consecutive rises (one week apart) in PSA with testosterone within castration levels (<50 ng/dL), and in accordance with the most recent recommendations by the “Prostate Cancer Clinical Trials Working Group” (PCWG2), eligible to treatment with Docetaxel plus prednisone.
3.	Bone metastasis(es) evident on bone scan with or without bone pain. Equivocal scan findings should be confirmed by independent imaging.
4.	Life expectancy of at least 3 months.
5.	ECOG performance status score ≤ 2.
6.	Written informed consent.

E.4 Principal exclusion criteria: 1.	Predominance of visceral metastases
2.	Patients with risk of pathologic bone fracture who need immediate intervention.
3.	 Previous chemotherapy within the last 5 years.
4.	 Previous external beam therapy on more than 30% of bone marrow.
5.	Any of the following abnormal baseline hematological values:
•	Hemoglobin < 9 g/dL
•	White Blood Cells < 3 x 10 exp9/L
•	Neutrophils < 1.5 x 10 exp9/L
•	Platelets  < 100 x 10 exp9/L
6.	Any of the following abnormal baseline liver function tests:
•		Total serum bilirubin > 1.5 x ULN (upper limit of normal)
•	        SGPT/ALT and SGOT/AST > 1.5 x ULN
7.	Abnormal renal function test
•	Serum creatinine > 1.5 x ULN
8.	Very extensive bone metastatic involvement, such as “superscan” on scintigraphy.
9.	Flutamide, Finasteride, Bicalutamide, megestrol acetate, cyproterone acetate or nitulamide within 6 weeks of randomization. 
10.	Cardiovascular: clinically relevant abnormalities, myocardial infarctions or other severe coronary artery disease within the prior six months, cardiac arrhythmia requiring medication or uncontrolled arterial hypertension.
11.	Cardiac failure or non-compensated active heart disease (> class II of NYHA classification).
12.	Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma in situ.
13.	Any other investigational drug within 4 weeks of study entry.
14.	Known hypersensitivity to the active substances of Quadramet® or Taxotere® or to any of their respective excipients.

E.5 End points
E.5.1 Primary end point(s): Time-to-progression which is defined by the time from the first study drug administration until documented disease progression.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: Yes
E.6.13.1 Other scope of the trial description: Quality of life and pain assessment
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 7
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 20
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 3
E.8.9.1 In the Member State concerned months: 6
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 3
E.8.9.2 In all countries concerned by the trial months: 6

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: No
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: No
F.3.3.1 Women of childbearing potential not using contraception : Information not present in EudraCT
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: Information not present in EudraCT
F.3.3.4 Nursing women: Information not present in EudraCT
F.3.3.5 Emergency situation: Information not present in EudraCT
F.3.3.6 Subjects incapable of giving consent personally: Information not present in EudraCT
F.3.3.7 Others: Information not present in EudraCT
F.4 Planned number of subjects to be included
F.4.1 In the member state: 90
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 308
F.4.2.2 In the whole clinical trial: 308

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2009-07-08
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2009-08-04

P. End of Trial
P. End of Trial Status: Ongoing

